Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DS-1103a · 1 trial · 1 indication
Objective response rate (ORR) is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) as assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria In Solid Tumors v1.1.
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: DS-1103a + T-DXd | EXPERIMENTAL | Participants with HER2-expressing or HER2-mutated advanced metastatic solid tumors who will receive an escalating intravenous (IV) infusion of DS-1103a (starting dose of 100 mg) every 3 weeks (Q3W) starting on Cycle 1 Day 1. Starting on Cycle 2 Day 1 and on Day 1 of each subsequent cycle, participants will also receive T-DXd IV Q3W. |
| Dose Expansion (Cohort 1): DS-1103a + T-DXd | EXPERIMENTAL | Participants with a specific HER2-altered advanced solid tumor type who will receive an IV infusion of DS-1103a at the recommended dose for expansion (RDE) in combination with T-DXd IV Q3W starting on Cycle 1 Day 1. |
| Dose Expansion (Cohort 2): DS-1103a + T-DXd | EXPERIMENTAL | Participants with a specific HER2-altered advanced solid tumor type who will receive an IV infusion of DS-1103a at the recommended dose for expansion (RDE) in combination with T-DXd IV Q3W starting on Cycle 1 Day 1. |
| Name | Type | Description |
|---|---|---|
| DS-1103a | DRUG | One IV infusion Q3W on Day 1 of each 21-day cycle |
| T-DXd | DRUG | One IV infusion Q3W on Day 1 of each 21-day cycle |
Inclusion Criteria: * Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures * Adults ≥18 years of age at the time the ICF is signed (please follow local regulatory requirements if the legal age of consent for study participation is \>18 yea...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
DS-1103a is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
DS-1103a is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate this investigational drug candidate for the treatment of advanced solid tumors.
DS-1103a is currently in Phase 1 clinical development. This is an early stage of testing in humans, focused on evaluating the drug's safety, tolerability, and preliminary efficacy. The drug is investigational and has not yet received regulatory approval for any indication.
DS-1103a is being studied in a Phase 1 clinical trial with the identifier NCT05765851. This trial is titled 'A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors' and is currently recruiting participants in the United States, Canada, France, and Spain.
DS-1103a is being studied as a combination therapy in its current clinical trial. The Phase 1 study, NCT05765851, is evaluating DS-1103a in combination with other agents in participants with advanced solid tumors. The trial is a controlled study, though it is not randomized or double-blinded.
Yes, the DS-1103a clinical trial is biomarker-selected. This means that the study may enroll patients based on specific biomarkers, which could help identify individuals who are more likely to respond to the treatment. The trial is currently recruiting participants with advanced solid tumors.